中华实验和临床病毒学杂志最新文献_第4页

[Clinical trial on the prevention of diarrhea by oral BIFICO for infants aged 1-6 years]. [口服BIFICO预防1-6岁婴幼儿腹泻的临床试验]。

中华实验和临床病毒学杂志 Pub Date : 2013-08-01

Xiao-Ling Liu, Meng-Lei Li, Wen-Xia Ma, Sheng-Li Xia, Bian-Li Xu

{"title":"[Clinical trial on the prevention of diarrhea by oral BIFICO for infants aged 1-6 years].","authors":"Xiao-Ling Liu, Meng-Lei Li, Wen-Xia Ma, Sheng-Li Xia, Bian-Li Xu","doi":"","DOIUrl":"","url":null,"abstract":"Objective: To investigate the prevention of diarrhea by oral BIFICO for infants aged 1-6 years.Methods: 490 cases of infants were randomly divided after age stratification: the experimental group (n = 247) and the control group (n = 243). Based on principles of randomized double-blind and placebo-controlled, the infants were given BIFICO (dedicated clinical research)therapy for 4 consecutive days, then observed for 21 days. 25 days composed a cycle. They were observed total 5 cycles. During the study period, principles for \"the diarrhoea patients must be detected\", follow-up visited the participant infants and conducted etiology detection by way of sampling for diarrhea infants. Evaluate the prevention efficacy of diarrhea by oral BIFICO for infants aged 1-6 years.Results: A total of 480 completed all study. 120 and 95 infants in the control group and experimental group were detected with diarrhea. The incidence of diarrhea was 50.85% and 38.93% in these two guoup, respectively. The difference has statistical significance (chi2 = 4.175, P = 0.041). In the third observation period, the infants in the control group had a higer incidence of diarrhea compared with which in the experimental group (chi2 = 4.415, P = 0.036). 14 strains of rotavirus, 3 strains of norovirus, 3 strains of sappovirus, 2 strains of adenovirus, 5 strains of salmonella and 4 strains of Shigella were check out in 128 samples.Conclusion: Oral BIFICO can paly certain preventive role on diarrhea, and decrease the incidence of diarrhea in infants aged 1-6 years.","PeriodicalId":70973,"journal":{"name":"中华实验和临床病毒学杂志","volume":"27 4","pages":"277-9"},"PeriodicalIF":0.0,"publicationDate":"2013-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32161860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Establishment of a detection method for hepatitis B virus large surface protein (HBV-lP)]. 乙型肝炎病毒大表面蛋白(HBV-lP)检测方法的建立。

中华实验和临床病毒学杂志 Pub Date : 2013-08-01

Jing Zhao, Hong-Bin Ma, Jun Hou, Jing-Xia Guo, Jun Xu, Yong-Ji Song, Lin Chen, Ai-Xia Liu, Jia Liu, Hong-Shan Wei, Bo-An Li

引用次数: 0

[Interleukin-32 expression in serum of patients with HBV-related liver failure and its significance]. [乙型肝炎相关性肝衰竭患者血清白细胞介素-32表达及意义]。

中华实验和临床病毒学杂志 Pub Date : 2013-08-01

Gui-Long Zhuang, Guo-Hang Li, Zhi-Jun Qu, Jian-Yu Kuang

{"title":"[Interleukin-32 expression in serum of patients with HBV-related liver failure and its significance].","authors":"Gui-Long Zhuang, Guo-Hang Li, Zhi-Jun Qu, Jian-Yu Kuang","doi":"","DOIUrl":"","url":null,"abstract":"Objective: To investigate the expression level of IL-32 in serum and its correlation with serum biochemical indices of liver function test and HBV DNA load in patients with HBV-related liver failure.Methods: Fifty-five patients with HBV-related liver failure (severe hepatitis group) and twenty normal cases (control group) were enrolled in the study. Total RNA in PBMCs was extracted by using TRIzol. IL-32 mRNA level was assayed by using Real-time PCR. IL-32 protein level in serum was detected by ELSIA method. The correlation between IL-32 and ALT, AST, TBIL, HBV DNA load was analyzed using pearson's correlation analysis, respectively.Results: Serum IL-32 expression level in severe hepatitis group was higher than that of control group. Moreover, the difference between them was statistically significant (P < 0.05). Serum IL-32 level was positively correlated with serum ALT, AST, TBIL, respectively (P < 0.05), but was not correlated with HBV DNA load (P > 0.05).Conclusion: Serum IL-32 expression level was increased in patients with HBV-related liver failure and was associated with the severity of inflammation. We, therefore, believe that IL-32 might be involved in the pathogenesis of HBV-related liver failure.","PeriodicalId":70973,"journal":{"name":"中华实验和临床病毒学杂志","volume":"27 4","pages":"247-9"},"PeriodicalIF":0.0,"publicationDate":"2013-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32161328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Expression and bioassay of rubella virus E1-374 glycoprotein in yeast cells]. 风疹病毒E1-374糖蛋白在酵母细胞中的表达及生物测定

中华实验和临床病毒学杂志 Pub Date : 2013-08-01

Zhen-Mei Li, Hong-Ling Wen, Bin Lin, Cheng-Xi Sun, Fu-Lu Chu, Xiao-Jing Yuan, Yan-Yan Song, Hong-Zhi Xu, Zhi-Yu Wang

引用次数: 0

[To investigate the opportunity of entecavir treatment for HBeAg-negative acute-on-chronic liver]. [目的探讨恩替卡韦治疗hbeag阴性急慢性肝病的时机]。

中华实验和临床病毒学杂志 Pub Date : 2013-08-01

Li Mai, Ying Yan, Shao-Quan Zhang, Wei-Min Ke, Hong Cao

{"title":"[To investigate the opportunity of entecavir treatment for HBeAg-negative acute-on-chronic liver].","authors":"Li Mai, Ying Yan, Shao-Quan Zhang, Wei-Min Ke, Hong Cao","doi":"","DOIUrl":"","url":null,"abstract":"Objective: To explore relations between the opportunities and effects of internal general treatment added Entecavir on acute-on-chronic liver failure (ACLF) of HBeAg-negative chronic hepatitis B in different score ranges of acute-on-chronic liver failure severity.Methods: A total of 108 ACLF of HBeAg-negative chronic hepatitis B patients with different ACLF severity score were treated with internal general treatment added Entecavir. The liver failure severity scores, HBV-DNA loads during the initiation of therapy, recovery phase and in deathbed phase, courses of Entecavir administration and mortalities were studied.Results: For 19 patients with high ACLF score (> or = 12), the difference in ACLF score between pre and post-treatment was not significant. The difference in HBV-DNA load between pre and post-treatment was not significant and the mortality was 18/19. For 30 patients with higher intermediate ACLF score (8-11), the difference in ACLF score between pre and post-treatment was not significant. The difference in HBV-DNA load between pre and post-treatment was significant, and the mortality was 66.67% (20/30). For 36 patients with lower intermediate ACLF score (5-7), the difference in ACLF score between pre and posttreatment was not significant. The difference in HBV-DNA load between pre and post-treatment was significant, and the mortality was 30.56% (11/36). For 23 patients with low ACLF score (< or = 4), the difference in ACLF score between pre and post-treatment was significant. The difference in HBV-DNA load between pre and post-treatment was significant, and the mortality was 8.70% (2/23).Conclusions: A novel acute-on-chronic liver failure scoring system can syllabify differentiate the relations between the opportunities and efficacies on the Entecavir treatment for HBeAg-negative ACLF.","PeriodicalId":70973,"journal":{"name":"中华实验和临床病毒学杂志","volume":"27 4","pages":"286-8"},"PeriodicalIF":0.0,"publicationDate":"2013-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32161863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Serum GP73 were increased in patients with fatty liver disease]. [脂肪肝患者血清GP73升高]。

中华实验和临床病毒学杂志 Pub Date : 2013-08-01

Hong-Shan Wei, Yan-Fang Kang, Xiao-Hua Hao, Jia Liu, Hong-Min Li, Ai-Xia Liu, Hui Ren, Yu-Bo Huang, Bo-An Li

{"title":"[Serum GP73 were increased in patients with fatty liver disease].","authors":"Hong-Shan Wei, Yan-Fang Kang, Xiao-Hua Hao, Jia Liu, Hong-Min Li, Ai-Xia Liu, Hui Ren, Yu-Bo Huang, Bo-An Li","doi":"","DOIUrl":"","url":null,"abstract":"Objective: To explore the levels of serum GP73 in patients with fatty liver disease.Methods: The sera GP73 were determined by ELISA in 178 patients with fatty liver disease and 100 healthy controls.Results: Serum GP73 levels were significantly increased in patients with various fatty liver diseases(70.62 +/- 60.60 ng/ml), compared with those of control population (35.61 +/- 12.22 ng/ml). In patients with alcoholic fatty liver disease, acute liver injury, chronic hepatitis B, and non-alcoholic fatty liver disease, their serum GP73 concentration were 81.86 +/- 47.82 ng/ml, 82.77 +/- 77.73 ng/ml, 63.84 +/- 50.62 ng/ml, and 65.75 +/- 62.20 ng/ml, respectively. But no significant difference was found between these groups (P > 0.05). In 68 patients with F > or = 1.0 (71.46 +/- 66.48 ng/ml), 75 patients with F> or = 2.0 (69.58 +/- 62.31 ng/ml), and 34 patients with F3-F4 (71.65 +/- 43.89 ng/ml), there were also no marked differences was observed between these fatty groups (F = 0.02, P = 0.98).Conclusion: Serum GP73 levels were increased in patients with different liver diseases, but its concentrations were seems not related with degree of fatty injury.","PeriodicalId":70973,"journal":{"name":"中华实验和临床病毒学杂志","volume":"27 4","pages":"244-6"},"PeriodicalIF":0.0,"publicationDate":"2013-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32161942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Construction of recombinant CHO cell strain for high expression of HBsAg]. 高表达HBsAg重组CHO细胞株的构建

中华实验和临床病毒学杂志 Pub Date : 2013-08-01

Yao Yi, Min-Zhuo Guo, Rui-Guang Tian, Qiu-Dong Su, Xue-Xin Lu, Feng Qiu, Wen-Ting Zhou, Zhi-Yuan Jia, Sheng-Li Bi

引用次数: 0

[Microplate chemiluminescence enzyme immunoassay for the quantitative analysis of tissue inhibitor of metalloproteinases I]. [微孔板化学发光酶免疫分析法用于金属蛋白酶组织抑制剂的定量分析]。

中华实验和临床病毒学杂志 Pub Date : 2013-08-01

Jun Hou, Jian Zhang, Jia Liu, Jing Zhao, Jing-Xia Guo, Lin Cheng, Jun Xu, Ai-Xia Liu, Yong-Ji Song, Bo-An Li, Hong-Shan Wei

{"title":"[Microplate chemiluminescence enzyme immunoassay for the quantitative analysis of tissue inhibitor of metalloproteinases I].","authors":"Jun Hou, Jian Zhang, Jia Liu, Jing Zhao, Jing-Xia Guo, Lin Cheng, Jun Xu, Ai-Xia Liu, Yong-Ji Song, Bo-An Li, Hong-Shan Wei","doi":"","DOIUrl":"","url":null,"abstract":"Objective: To establish microplate chemiluminescence enzyme immunoassay (CLEIA) for quantitative analysis of tissue inhibitor of metalloproteinases I (TIMP I) in human serum.Methods: A sandwich reaction was preformed with horseradish peroxidase(HRP) labeled monoclonal antibody of TIMP I as the catalytic enzyme and the H2O2-luminol as the luminescence reagent. Several physical and chemical parameters were studied and optimized such as immunoreaction conditions, the dilution ratio of TIMP I-HRP, luminescence reaction time and so on. In order to evaluate the method, recovery test, heat stabilization test and comparison test were carried out.Results: The linear range was 0. 2-12 ng/ml with r = 0.996. The detection limit was 0.12 ng/ml. Inter-assay and intra-assay RSD were both less than 10%. The recoveries of three different spiked concentration samples were 100.6%, 96.5% and 106.5%. After stored at 4 degrees C and 37 degrees C for 3, 5, 7 days, the analysis showed correlation coefficient higher than 0. 998 and RSD lower than 6%. The detected results with CLEIA closely corresponded to those with imported ELISA in 60 patients sera with liver fibrosis.Conclusion: Established CLEIA for quantity determination of serum TIMP I has high accuracy, sensitivity and repeatability.","PeriodicalId":70973,"journal":{"name":"中华实验和临床病毒学杂志","volume":"27 4","pages":"298-300"},"PeriodicalIF":0.0,"publicationDate":"2013-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32161784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Study on the etiology of acute hepatitis hospitalized patients in Beijing Ditan Hospital from 2002 to 2011]. 2002 - 2011年北京地坛医院急性肝炎住院患者病因分析

中华实验和临床病毒学杂志 Pub Date : 2013-08-01

Ge Shen, Lu Zhang, Yan-Li Zhang, Lei-Ping Hu, Ming-Hui Li, Yao Lu, Xing-Hong Li, Guo-Hua Qiu, Li-Wei Zhuang, Cai-Qin Mu, Hui Zhao, Li-Jun Chen, Min Yang, Yun-Zhong Wu, Yao Xie, Jun Cheng, Dao-Zhen Xu

{"title":"[Study on the etiology of acute hepatitis hospitalized patients in Beijing Ditan Hospital from 2002 to 2011].","authors":"Ge Shen, Lu Zhang, Yan-Li Zhang, Lei-Ping Hu, Ming-Hui Li, Yao Lu, Xing-Hong Li, Guo-Hua Qiu, Li-Wei Zhuang, Cai-Qin Mu, Hui Zhao, Li-Jun Chen, Min Yang, Yun-Zhong Wu, Yao Xie, Jun Cheng, Dao-Zhen Xu","doi":"","DOIUrl":"","url":null,"abstract":"Objective: To explore the etiology of acute hepatitis hospitalized patients in Beijing Ditan Hospital from 2002 to 2011.Methods: We summed up the changes in the characteristics of the etiology of acute hepatitis of patients mentioned above, and preliminarily analyze the causes.Results: From 2002 to 2011, 6235 patients with acute hepatitis were admitted to Ditan Hospital, aged between 12 and 78 years old, Of which 4309 were male and 1926 female. Acute viral hepatitis accounted for 70.44%-85.07%, while CMV, EBV, drug-induced liver injury accounted less than 5%, and acute hepatitis D and acute hepatitis C less than 1.10%. From year to year, the incidence and constitution of acute hepatitis changed significantly. The proportion of patients with acute hepatitis in total hospitalized patients was from 20. 38% to 2.05%. In 10 years, the percentage of acute hepatitis A decreased most obviously, about 99.11%, while 45.07% decline in incidence of acute hepatitis B and 62. 28% of acute hepatitis E. The constituent ratio of acute hepatitis also changed significantly. The proportion of acute hepatitis A declined from 31.31% in 2002, to less than 1% in 2011. The proportion of acute hepatitis B increased from 26.47% in 2002 to 45.88% in 2011, an increase of about 2 folds in 10 years. The proportion of acute hepatitis E increased from 26.73% in 2002 to 32.05% in 2010, a rise of 1.20 times in 10 years.Conclusions: The proportion of patients with acute hepatitis in total hospitalized patients decreased from 20. 38% in 2002 to 2. 05% in 2011 in Beijing Ditan Hospital. The constituent ratio of acute hepatitis changed, too.","PeriodicalId":70973,"journal":{"name":"中华实验和临床病毒学杂志","volume":"27 4","pages":"266-9"},"PeriodicalIF":0.0,"publicationDate":"2013-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32161334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Performance evaluation of TP antibody detection by CLIA kits made (in China) domestically]. 【国产CLIA试剂盒检测TP抗体性能评价】。

中华实验和临床病毒学杂志 Pub Date : 2013-08-01

Yu-Qing Jiang, Zhi-Xian Xie, Wen-Dan Fang, Tianyi Liu

引用次数: 0